梅州哪家医院治无痛人流好梅州子宫附件炎 症状,梅州医院妇科在线咨询,梅州薇薇打胎费用,梅州处女膜修复大约需花多少,梅州哪家治疗妇科病的医院好,梅州人流时间怎么计算,梅州超导人流医院哪家好

BEIJING, Jan. 5 (Xinhua) -- The U.S. Secretary of Treasury Timothy Geithner will visit China from Jan. 10 to 11 as a special representative of the U.S. President Barack Obama, Chinese Foreign Ministry spokesman Hong Lei announced on Thursday.Timothy Geithner's visit is at the invitation of Chinese Vice Premier Wang Qishan, said Hong.Chinese top leaders will meet with Timothy Geithner and exchange views with him on issues concerning Sino-US economical relations and the world's economic and financial situations, Hong said.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

MOSCOW, Oct. 3 (Xinhua) -- A Soyuz-2.1B rocket carried a Glonass-M navigation satellite into orbit early Monday after a two-day delay caused by high winds, a Russian Space Forces spokesman said."The launch of the booster rocket is as scheduled. The satellite Glonass-M was put into the orbit under control at 03:55 Moscow time (2355 GMT on Sunday)," said Colonel Alexei Zolotukhin.Zolotukhin told reporters that the rocket was launched at 0:15 Moscow time (2015 GMT, Sunday) from the Plesetsk Space Center in northern Russia.The Russian Space Forces said the launch was initially scheduled for Saturday but was postponed due to high winds.Glonass is the Russian equivalent of the U.S. Global Positioning System (GPS), which is designed for both military and civilian use. The system requires 24 operational and 2-3 reserve satellites in orbit to ensure global coverage.In December 2010, a malfunction of the booster resulted in a loss of three Glonass satellites.

JERUSALEM, Jan. 12 (Xinhua) -- An Israeli company has developed a system that scans the brain and provides a three dimensional image of the nerve cell connectivity to treat brain diseases like Alzheimer's or HDHD.The firm ElMindA trademarked a non-invasive system, the BNA ( Brain Network Activation), that helps doctors visualize the connectivity between nerve cells and synchronization that can even measure the severity of the patients condition from one day to another, the Israel21c news site reported on ThursdayBy creating a three-dimensional image of the brain while asking the patients to repeat an activity several times, BNA developers hope this system will become a regular way of diagnosing brain illnesses."Our vision is that every psychiatrist and neurologist in the world will routinely send every patient for BNA tests," said Dr. Eli Zangvil, ElMindA's strategic advisor for business development. "Our test would add information and aid in diagnostics in a way no other existing technology can do," he added.BNA could help doctors find out exactly at what stage of the disease patients and prescribe the exact medication for them."To do that, we must collect a lot of data," Zangvil said. "To say this person has a certain disease or condition, I have to be able to compare their pattern to a normal brain pattern of a person of the same age and gender." he said.Researchers hope to gather the amount of data they need to obtain FDA approval in the U.S. by the end of 2012, and start marketing it to hospitals by 2013.

BEIJING, Dec. 16 (Xinhua) -- Trade volume between China and the Association of Southeast Asian Nations (ASEAN) in 2010 was 36 times what it was in 1991, the year in which formal relations between the two sides were established, according to new statistics.The volume is expected to reach 500 billion U.S. dollars in 2015, according to figures revealed Friday at the China-ASEAN Beijing Economic Forum, an event taking place in China's capital from Dec. 16 to 18 to commemorate the 20th anniversary of the China-ASEAN relations.Ma Mingqiang, secretary-general of ASEAN-China Center, said China-ASEAN trade volume totaled 267 billion U.S. dollars in the first three quarters of 2011 and is expected to hit the annual target of 350 billion dollars this year.He said the two parties have become closely linked in the past two decades, as China is now ASEAN's largest trade partner while ASEAN ranks the third among China's trade partners.With the comprehensive implementation of the China-ASEAN Free Trade Agreement in 2010, China has made 90 percent of commodities traded between China and ASEAN countries free of tariffs.China and ASEAN have enjoyed rapid social and economic growth since they established bilateral cooperation, said Surin Pitsuwan, ASEAN secretary-general.ASEAN can provide human resources, natural resources and raw materials for China's industrial development, and it in turn wants to win more investment from China, said Pitsuwan.He said the cooperation not only is a win-win solution for both sides, but will also make a positive contribution to the world.Guo Jinlong, mayor of Beijing, said the city saw a 21.5 percent year-on-year increase in trade volume with ASEAN in 2010, and will further strengthen its cooperation with the countries.ASEAN groups Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam.